Dr Abraham Heifets

Founder, Atomwise

Atomwise’s technology is a virtual drug discovery platform based on the science of Deep Learning Neural Networks, and has previously been used for research on Malaria, Multiple Sclerosis, C. Difficile, and Leukemia. In 2014, Atomwise began an initiative to search for new treatments for the Ebola virus using artificial intelligence. Atomwise completed Y-Combinator in 2014 and has gone on to raise over $6 million dollars in seed funding.

Abraham is an expert in big data and high-performance computing. After completing his B.Sc. and M.Eng. at Cornell, Abraham worked on high-performance computing at IBM's T.J. Watson Research Center. As a doctoral candidate at the University of Toronto, Abraham created SCRIPDB, one of the largest public databases of patented chemical structures, and LigAlign, a protein analysis tool used by researchers in 70 countries. Abraham was also named a fellow of Massey College and the Ontario Brain Institute.

“We are going to explore the possible effectiveness of millions of drugs, something that used to take decades of physical research and tens of millions of dollars, in mere days with our technology.” – Atomwise CEO, Dr. Abraham Heifets